The first Vietnamese case of COVID-19 acquired from China

Cường, Lê Văn; Giang, Hoang Thi Nam; Linh, Le Khac; Shah, Jaffer; Sy, Le Van; Hung, Trinh Huu; Reda, Abdullah; Truong, Luong Ngoc; Tien, Do Xuan; Huy, Nguyen Tien

doi:10.1016/s1473-3099(20)30111-0

Cited by 53 publications

(48 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corticosteroids use on the current outbreak was widely reported (Stockman et al, 2006;Guan et al, 2020;Huang et al, 2020;Wang et al, 2020a;Chen et al, 2020a;Xu et al, 2020c). However, the current evidence indicates that the benefit of general use is inconclusive and is likely outweighed by adverse effect (delayed viral clearance, avascular necrosis, osteoporosis, diabetes, psychosis) (Tsui et al, 2003;Arabi et al, 2018;Lansbury et al, 2019;Russell et al, 2020). As of 22 February 2020, the interim guideline of World Health Organisation (WHO) does not support the use of systemic corticosteroids for the treatment of viral pneumonia and ARDS for suspected COVID-19 cases (World Health Organization, 2020b).…”

Section: Management From Conventional Medicinementioning

confidence: 96%

“…At present, SARS-CoV-2 is believed to spread through contact, droplet or fomite (Van Cuong et al, 2020;World Health Organization, 2020a). Increasing evidence also points to the faecal-oral route Heymann and Shindo, 2020;Holshue et al, 2020;Yeo et al, 2020) and aerosol (National Health Commission and National Administration of Traditional Chinese Medicine, 2020).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease

2020

View full text Add to dashboard Cite

As of 22 February 2020, more than 77662 cases of confirmed COVID-19 have been documented globally with over 2360 deaths. Common presentations of confirmed cases include fever, fatigue, dry cough, upper airway congestion, sputum production, shortness of breath, myalgia/arthralgia with lymphopenia, prolonged prothrombin time, elevated C-reactive protein, and elevated lactate dehydrogenase. The reported severe/critical case ratio is approximately 7-10% and median time to intensive care admission is 9.5-10.5 days with mortality of around 1-2% varied geographically. Similar to outbreaks of other newly identified virus, there is no proven regimen from conventional medicine and most reports managed the patients with lopinavir/ritonavir, ribavirin, beta-interferon, glucocorticoid and supportive treatment with remdesivir undergoing clinical trial. In China, Chinese medicine is proposed as a treatment option by national and provincial guidelines with substantial utilization. We reviewed the latest national and provincial clinical guidelines, retrospective cohort studies, and case series regarding the treatment of COVID-19 by add-on Chinese medicine. We have also reviewed the clinical evidence generated from SARS and H1N1 management with hypothesized mechanisms and latest in silico findings to identify candidate Chinese medicines for the consideration of possible trials and management. Given the paucity of strongly evidence-based regimens, the available data suggest that Chinese

show abstract

Section: Management From Conventional Medicinementioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease

2020

View full text Add to dashboard Cite

show abstract

“…Recently, the World Health Organization (WHO) declared the coronavirus disease 2019 (COVID-19) to be an international public health emergency. Efficient human-tohuman communication appears to be a prerequisite for the widespread dissemination of this new virus (1)(2)(3)(4). Currently, COVID-19 has appeared in 190 nations, negatively affecting over 500,000 patients and threatening the remaining world population (Figure 1).…”

Section: Introductionmentioning

confidence: 99%

From First COVID-19 Case to Current Outbreak: A Vietnamese Report

Duc

Tuấn

et al. 2020

Electron J Gen Med

View full text Add to dashboard Cite

The 2019 novel coronavirus outbreak (now recognized as SARS-CoV-2, triggering the COVID-19 disease) has spread from Wuhan throughout China and has been distributed to an increasing range of countries. Early activity has concentrated on explaining the course of the disease, reporting critical incidents, and handling the ill. Currently, Vietnam, an Association of Southeast Asian Nations (ASEAN) country that shares a long border with China, has successfully controlled COVID-19. In this article, we aimed to provide updated information regarding COVID-19 in Vietnam, from the first case to the current outbreak. We hope the information in this article will help the world understand more about the surveillance and prevention policies of Vietnam's COVID-19. The numerous lessons learned will serve as a guide for handling possible pandemics, but a permanently new global framework is expected in the immediate future.

show abstract

“…In December 2019, the rst pneumonia case caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), now known as coronavirus disease 2019 (COVID- 19), was identi ed in Wuhan, Hubei Province, China [1]. SARS-Cov-2 infection is now quickly spreading globally [2,3]. Evidence shows that the person-to-person transmission is the main cause of the large-scale outbreak of COVID-19 [4].…”

Section: Introductionmentioning

confidence: 99%

The corticosteroid treatment and response of patients with COVID-19 in Hubei, China: a retrospective, cohort study

Shang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Since December 2019, COVID-19 has emerged in Wuhan, China and spread globally. As of now, there is still no explicit therapeutic regimen and the use of corticosteroid is also controversial. We aimed to explore the effectiveness of corticosteroid and provide evidence for the rational use of corticosteroid in different patients with COVID-19.Methods In this multi-centered, retrospective study, we extracted the clinical data of 649 cases with COVID-19 with definite outcome (discharged or dead) from 14 hospitals in Hubei province, and evaluated the clinical characteristics, treatment regimens, and their association with outcomes.Results Ninety-five of 649 patients had died. Older male patients with comorbidities had an increased risk of death and more obvious abnormalities in clinical indicators. Corticosteroid, γ-globulin treatment and invasive ventilation were more frequently used in non-survivors. Survivors with corticosteroid treatment had a prolonged hospitalization. The median time duration for temperature restore for non-survivors after corticosteroid treatment was longer than that of both survivors. The lymphocyte count on admission was lower in the patients treated with corticosteroids compared to those without corticosteroid treatment. Lymphocyte count recovered significantly after corticosteroid treatment in survivors, but not in non-survivors.Conclusions The responses to corticosteroid treatment were different in COVID-19 patients with different outcomes. The surviving patients with relatively lower lymphocyte count were more likely to be given corticosteroids. For non-survivors, the lymphocyte count was too low and the effect of corticosteroids was poor. Survivors under corticosteroid treatment had a prolonged hospitalization, but had a recovery of lymphocytes. The recovery of lymphocyte count and temperature after corticosteroid treatment may be used as predictors of prognosis of patients with COVID-19.

show abstract

The first Vietnamese case of COVID-19 acquired from China

Cited by 53 publications

References 0 publications

COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease

COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese–Western Medicine for the Management of 2019 Novel Coronavirus Disease

From First COVID-19 Case to Current Outbreak: A Vietnamese Report

The corticosteroid treatment and response of patients with COVID-19 in Hubei, China: a retrospective, cohort study

Contact Info

Product

Resources

About